Global RNA Therapeutics Market Report and Forecast 2024-2032

RNA Therapeutics Market Overview

RNA therapeutics involve using RNA molecules to treat diseases by targeting gene expression at the RNA level. Key approaches include mRNA therapies, which instruct cells to produce therapeutic proteins, RNA interference (RNAi) to silence harmful genes, and antisense oligonucleotides (ASOs) to modify RNA splicing or stability. These therapies have significant potential for treating genetic disorders, cancers, and viral infections. By directly targeting the root causes of diseases at a molecular level, RNA therapeutics offer a promising and innovative approach to medicine.

RNA Therapeutics Market Growth Drivers

Surge in FDA Approvals to Boost Market Value

The increasing prevalence of cancer and advancements in RNA-targeting technologies are significant drivers of market growth. In July 2024, Rgenta Therapeutics received FDA clearance for its Investigational New Drug (IND) application for RGT-61159, an innovative oral small molecule targeting RNA regulation. The drug is designed for the treatment of adenoid cystic carcinoma, colorectal cancer, solid tumors, and acute myeloid leukemia. This milestone highlights the shift toward RNA-based therapies in oncology. The approval is poised to accelerate investments in RNA-targeting drugs and expand the pipeline of RNA-based oncology treatments, boosting market value in the forecast period.

Rising Preference for Precision Medicine to Boost RNA Therapeutics Market Demand

Rising demand for precision medicine and breakthroughs in RNA-editing technologies drive market expansion. In November 2024, HuidaGene Therapeutics achieved FDA clearance for HG202, the first-ever CRISPR/Cas13 RNA-editing therapy designed for clinical use. This innovative treatment targets neovascular age-related macular degeneration, a leading cause of blindness. The development of HG202 underscores the growing potential of RNA-editing platforms. This approval is expected to foster competition, encourage global collaborations, and solidify RNA-editing’s role in addressing unmet medical needs, further enhancing the market’s growth trajectory during the forecast period.

RNA Therapeutics Market Trends

RNA Therapeutics Market Segmentation

RNA Therapeutics Market Share

Market Segmentation by Type to Witness Growth

The market share by type constitutes mRNA therapeutics, RNA interference (RNAi) therapeutics, antisense oligonucleotide (ASO) therapeutics and others. The mRNA therapeutics segment dominates the RNA therapeutics market by type, driven by the success of mRNA-based vaccines like those for COVID-19. Its rapid adaptability to emerging diseases and scalability in production gives it an edge.

RNA Therapeutics Market Analysis by Region

North America leads the market share due to its advanced healthcare infrastructure, strong presence of biotechnology companies, and significant investments in R&D. The region benefits from a high prevalence of target diseases, robust regulatory frameworks, and government funding supporting RNA-based drug development. Additionally, North America hosts leading players pioneering RNA technology, including mRNA vaccines and gene silencing therapies, driving rapid market growth. The early adoption of innovative therapies and strategic partnerships between academia and industry further strengthen its dominance. This competitive edge positions North America as the key driver of the market globally.

Leading Players in the RNA Therapeutics Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Moderna, Inc.

Headquartered in Cambridge, Massachusetts, USA, Moderna was founded in 2010. The company is a pioneer in messenger RNA (mRNA) technology, having gained global recognition for its COVID-19 vaccine, Spikevax. Moderna is also advancing mRNA-based therapeutics across multiple disease areas, including oncology, rare genetic disorders, and infectious diseases. Its expanding portfolio focuses on developing mRNA medicines that deliver genetic instructions to cells, offering potential treatments for previously hard-to-address conditions.

BioNTech SE

BioNTech, based in Mainz, Germany, was established in 2008. The company is a leader in the development of mRNA...

Alnylam Pharmaceuticals, Inc.

Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is a leader in RNA inte...

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, established in 1989 and headquartered in Carlsbad, California, specialises in antisense...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other key players in the market include Arcturus Therapeutics Holdings Inc., CureVac N.V., Sarepta Therapeutics, Inc., Wave Life Sciences Ltd., Sanofi S.A., and Novo Nordisk A/S.

Key Questions Answered in the RNA Therapeutics Market

• What was the RNA therapeutics market value in 2023?
• What is the RNA therapeutics market forecast outlook for 2024-2032?
• What is the market breakup based on the product?
• What is the market breakup based on the type?
• What is the market breakup based on the indication?
• What is the market breakup based on the end user?
• What are the major factors aiding the RNA therapeutics market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major RNA therapeutics market trends?
• Which product will lead the market segment?
• Which type will lead the market segment?
• Which indication will lead the market segment?
• Which end user will lead the market segment?
• Who are the key players involved in the RNA therapeutics market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?